Objective To evaluate the rationality of clinical application and safety of envolizumab,so as to pro-vide reference for the clinical use and management of immune checkpoint inhibitors(ICI).Methods The basic infor-mation,medication status,and occurrence of adverse drug reactions of the patients treated with envolizumab from April 2023 to December 2023 in Hefei Cancer Hospital,Chinese Academy of Sciences were collected for clinical application and safety analysis.Results A total of 63 patients were treated with envolizumab,82.54％of advanced solid tumors showed disease progression after previous treatment,and there wre some problems of off-label drug use on indication and inappropriate usage and dosage in clinical applications.The incidence of immune related adverse reactions(irAE)with envolizumab was 68.25％,mainly included blood toxicity(41.27％),digestive system symptoms(23.81％),and liver toxicity(20.63％).There was no significant correlation between the incidence of adverse reactions to envolizumab and the patient's gender,age,underlying disease,smoking history,drinking history,radiotherapy history and tumor type(P＞0.05),and the irAE'incidence of different drug doses of 200 mg and 400 mg was statistically significant(P＜0.05).Conclusions There are widespread of unreasonable use of envolizumab in the real world.The clinical application of ICI should be based on evidence-based medicine and pay attention to the irAE,and the department of pharmacy should en-hance prescription audit and prescription comment to jointly ensure safe medication for patients.
Inappropriate prescribingDrug-related side effects and adverse reactionsEnvolizumabImmune checkpoint inhibitorsClinical study
维普
万方数据
